



Adams Business Associates.

Tel: 44-(0)1494-465244

Email: aba@a-b-a.co.uk

Web site: www.aba-business.com

4th Edition – ABA Global Library of Products & Services for Life Science Research Markets - ABA 374.4 Western Europe – April 2020

1. Introduction & Purpose for the Western Europe Life Science Market Analysis	1
2. European Demographics	4
2.1. General Overview	4
2.2. Group 1 Countries [France, Germany, Italy, Switzerland & UK] Including Austria and Ireland	6
2.3. Group 2 – Nordic Countries [Denmark, Finland, Norway, Sweden & Iceland]	18
2.4. Group 3 – Benelux Countries [Belgium, The Netherlands & Luxembourg]	23
2.5. Group 4 – Iberian Countries [Portugal & Spain]	28
3. General Features for Western Europe – 2013/2019	32
3.1. General Introduction & EU Contribution	32
3.2. EU Projects & Funding 2019	42
4. Group 1 Countries – Life Science & BioResearch Analysis	63
4.1 France	63
4.1.1. French Structure & Funding	63
4.1.2. French Life Science & Biotechnology Business & Funding	74
4.1.3. French Regional & Business Structure	83
4.2. Germany	88
4.2.1. German Structure & Funding	88
4.2.2. German Life Science & Biotechnology Business & Funding	96
4.2.3. German Regional (Lander) & Business Structure	103



Adams Business Associates.

Tel: 44-(0)1494-465244

Email: aba@a-b-a.co.uk

Web site: www.aba-business.com

4.3. Italy	115
4.3.1. Italian Structure & Funding	115
4.3.2 Life Science & Biotechnology Italian Structure	118
4.3.3. Italian Regional & Business Structure	123
4.4. Switzerland	131
4.4.1. Swiss Structure & Funding	131
4.4.2. Swiss Life Sciences & Biotechnology Business Structure	135
4.4.3. Swiss Regional & Business Structure	137
4.5. United Kingdom	141
4.5.1. British Structure & Funding	141
4.5.2. British Life Science & Biotechnology Structure & Funding	149
4.5.3. British Regional & Business Structure	165
4.6. Austria	175
4.6.1. Austrian Structure & Funding	175
4.6.2. Austrian Life Science & Biotechnology Structure	177
4.6.3. Austrian Life Science & Biotechnology Regional Business Structure	179
4.7. Ireland	182
4.7.1. Irish Structure & Funding	182
4.7.2. Irish Life Science & Biotechnology Structure	185
4.7.3. Irish Regional Structure & Business	194
5. Group 2 Nordic Countries – Life Science & BioResearch Analysis	196
5.1. Denmark	196
5.1.1. Danish Structure & Funding	197
5.1.2. Danish Life Science & Biotechnology Structure & Business	197
5.1.3. Danish Regional & Business Structure	204



Adams Business Associates.

Tel: 44-(0)1494-465244

Email: aba@a-b-a.co.uk

Web site: www.aba-business.com

5.2. Finland	206
5.2.1. Finnish Business Structure & Funding	206
5.2.2 Finish Life Science & Biotechnology Structure	208
5.2.3. Finnish Regional Structure & Business	216
5.3. Norway	218
5.3.1. Norwegian Business Structure & Funding	218
5.3.2 Norwegian Life Science & Biotechnology Structure	219
5.3.3. Norwegian Regional & Business Structure	226
5.4. Sweden (& Scanbalt network)	228
5.4.1. Swedish Business Structure & Funding	228
5.4.2. Swedish Life Science & Biotechnology Structure & Funding	229
5.4.3. Swedish Regional & Business Structure	236
5.5. Iceland	245
5.5.1. Icelandic Structure & Funding	245
5.5.2. Icelandic Biotechnology Business Structure & Funding	246
5.6. Nordic Overview	252
6. Group 3 Benelux Countries – Life Science & BioResearch Analysis	253
6.1. Belgium	253
6.1.1. Belgian Business Structure & Funding	253
6.1.2. Belgian Life Science & Biotechnology Structure & Funding	254
6.1.3. Belgian Regional Structure & Business	256
6.2. The Netherlands	267
6.2.1. Dutch Business Structure & Funding	267
6.2.2. Dutch Life Science & Biotechnology Structure & Funding	270
6.2.3. Dutch Regional Structure & Business	275



6.3. Luxembourg	281
6.3.1. Luxembourg Business Structure & Funding	281
6.3.2. Luxembourg Life Science & Biotechnology Business & Funding	282
6.4. Benelux Overview	287
7. Group 4 Iberian Countries - Life Science & BioResearch Analysis	288
7.1. Spain	288
7.1.1. Spanish Business Structure & Funding	288
7.1.2. Spanish Life Science & Biotechnology Structure & Funding	289
7.1.3. Spanish Regional Structure & Business	296
7.2. Portugal	301
7.2.1. Portuguese Business Structure & Funding	301
7.2.2. Portuguese Life Science & Biotechnology Structure & Funding	302
7.3. Funding Sources for the Iberian Countries	310
8. Biotechnology Applications & Products	311
8.1. General Overview 2020	311
8.2. Red (or Healthcare) Biotechnology in Europe	315
8.3. Agricultural Biotechnology (Ag/Bio) in Europe	321
8.4. Blue Biotechnology	324
8.5. Industrial (White & Grey) Biotechnology	326
8.6. Major Technology Trends in Europe	333
8.6.1. Established Newer Technologies	333
8.6.2. New Developing Technologies	340
Global Virus Issues	341
Genetic Manipulation: CRISPR-R etc., Regeneration & Gene Therapy	343
CAR-T Cell Therapies	345
Further Developments of Next Generation Sequencing, NGS	347
Microbiome Analysis & Applications	348
Antibiotic Resistance and Sepsis	349
8.7. Application Markets in Europe, 2019 to 2024	352



Adams Business Associates.

Tel: 44-(0)1494-465244

Email: aba@a-b-a.co.uk

Web site: www.aba-business.com

9. Biotechnology Market Segments & Funding	353
9.1. Biotechnology Segments Description & Dynamics	353
9.2. Biotechnology Funding & Segment Allocations	357
9.3. Biotechnology Segment Development	365
10. BioResearch Product Quantification & Projection	368
10.1. Market Overview	368
10.2. Western Europe Product Group Totals & Growth	370
10.3. Country by Country Product Group Totals	372
10.4. Product Class Analysis for Product Groups	376
10.5. Market Trends Impacting Future Markets	381
10.6. Future Market Projections for Product Groups & Product Classes	390
10.7. Commercial Overview	392
Appendix 1 - Currency Conversions: December 2016 & 2019	395
Appendix 2 - BioResearch Product Descriptions, December 2019	396



FIGURES

1. Introduction & Purpose for the Western Europe

Life Science Market Analysis _____ 1

Figure 374.4.1 Other Reports for ABA Global Library for Life Science Research _____ 1

Figure 374.4.2 ABA Global Library for Life Science Research Reports – 2019 Status _____ 2

2. European Demographics _____ 4

Figure 374.4.3 General Features of Group 1 – France, Germany, Switzerland & UK _____ 7

Figure 374.4.4 General Features of Group 1 – Italy, Austria & Ireland _____ 8

Figure 374.4.5 Demographic & Healthcare Profiles – France, Germany, Switzerland & UK, 2019 _____ 9

Figure 374.4.6 Demographic & Healthcare Profiles – Italy, Austria & Ireland, 2016 _____ 9

Figure 374.4.7. General Events in 2018/2019 - France. _____ 10

Figure 374.4.8. General Events in 2018/2019 – Germany 1 & 2 _____ 11 12

Figure 374.4.9. General Events in 2018/2019 – Switzerland _____ 13

Figure 374.4.10 General Events in 2018/2019 – Austria _____ 13

Figure 374.4.11 General Events in 2018/2019 – United Kingdom 1 to 4 _____ 14- 17

Figure 374.4.12 General Features of Group 2 Countries – Denmark, Finland, Norway Sweden & Iceland _____ 19

Figure 374.4.13 Demographic & Healthcare Profiles – Denmark, Finland, Norway & Sweden 2019 _____ 20

Figure 374.4.14 General Events in 2018/2019 – Denmark & Finland _____ 21

Figure 374.4.15 General Events in 2018/2019 – Norway, Sweden & Iceland _____ 22

Figure 374.4.16 Features of Group 3 Countries – Belgium, Netherlands, Luxembourg _____ 25

Figure 374.4.17 Demographic & Healthcare Profiles – Belgium, Netherlands, Luxembourg, 2019 _____ 26

Figure 374.4.18 General Events in 2018/2019 – Benelux _____ 27



Figure 374.4.19 General Features of Group 4 Countries – Spain and Portugal	30
Figure 374.4.20 Demographic & Healthcare Profiles – Spain and Portugal, 2016	30
Figure 374.4.21 General Events in 2018/2019 – Iberian Countries	31
3. General Features for Western Europe – 2013/2019	32
Figure 374.4.22 Life Science Regional Funding Overview by Source of Investment, '19	35
Figure 374.4.23 European Market Features	38
Figure 374.4.24 General Events in 2018/2019 – EU & Linked Countries – 1 & 2	40 - 41
Figure 374.4.25 Overall Horizon 2020 Budget in Year 2020 Forma	44
Figure 374.4.26 EU Typical Health Call Projects	46
Figure 374.4.27 EU HP7 & Horizon 2020 Programmes, 2012-2019+	47 - 52
Figure 374.4.28 European Innovative Medicines Initiative Call Project Summary	55 - 57
Figure 374.4.29 European Molecular Biology Laboratory Funding, 2016 vs. 2018	58
Figure 374.4.30 EU Project Developments 2018/2019	62
4. Group 1 Countries – Life Science & BioResearch Analysis	63
Figure 374.4.31. French Biotechnology Organisations by Region, 2018	65
Figure 374.4.32 French Promotional Platform for Biotechnology	66
Figure 374.4.33. Biotechnology Funding Projects in France from <i>Investissements d'avenir</i> .	69
Figure 374.4.34 French Research Institute Budgets 2012-2019	70
Figure 374.4.35. French Research Funding – 1 in 2016	70
Figure 374.4.36. French Research Funding – 2 in 2017	71
Figure 374.4.37. French Research Funding – 3 in 2018 – 2019	71
Figure 374.4.38. French Research Funding – 4 in 2020	72
Figure 374.4.39 French IHU Projects	73
Figure 374.4.40 French Budget & Biotechnology Funding	73
Figure 374.4.41. French Biotechnology Sector Development & Changes	76
Figure 374.4.42 Biotechnology Funding & General Status in France	77
Figure 374.4.43 Life Sciences VC Investment in France by Sector, 2019	80
Figure 374.4.44 French Biotechnology Company Application Areas, 2019	81

Figure 374.4.45 Biotechnology Application Areas & Companies in France, 2019	82
Figure 374.4.46 Genopole Clusters in France	83
Figure 374.4.47 BioValley Cluster	85
Figure 374.4.48 Regional Biotechnology in France	87
Figure 374.4.49 Germany Market Promotional Features, 2019	90
Figure 374.4.50 Federal German Budget Allocations for 2019	92
Figure 374.4.51 BMBF Budget Allocations, 2019	94
Figure 374.4.52 Major Research Institute Funding Status in Germany, 2019 vs. 2016	95
Figure 374.4.53 Biotechnology Funding Status in Germany, 2019/20	97
Figure 374.4.54 German Life Sciences Research Funding Sources, 2019	98
Figure 374.4.55 German Biotechnology Applications, 2019	101
Figure 374.4.56 Data Base of German Biotechnology Companies, 2019	102
Figure 374.4.57 Biotechnology Status for German Lander, 2019	103
Figure 374.4.58 Biotechnology for Key German Lander	104
Figure 374.4.59 German BioClusters: Bavaria	107
Figure 374.4.60 German BioClusters: North Rhineland Westphalia, NRW	108
Figure 374.4.61. German BioClusters: Baden-Wurtemberg Biotechnology Applications, 2018	109
Figure 374.4.62 German BioClusters: Heidelberg & Baden-Wurtemberg	110
Figure 374.4.63 German BioClusters: Berlin – Brandenburg	111
Figure 374.4.64 German BioClusters: Hessen	112
Figure 374.4.65 German BioClusters: Other Regional Clusters	113
Figure 374.4.66 Italian Market Promotional Features, 2019	115
Figure 374.4.67. Italian Industrial Biotechnology Description, 2018/19	118
Figure 374.4.68 Italian Biotechnology Research Centres, 2019/20	119
Figure 374.4.69 Italian Biotechnology Funding Status, 2019	120
Figure 374.4.70 Italian Industrial Biotechnology Research Funding 2009 – 2019	120
Figure 374.4.71 Biotechnology Application Areas by Company, 2019	122

Figure 374.4.72 Biotechnology Science Parks in Italy Summary Chart, 2019	<u>123</u>
Figure 374.4.73. Distribution of Core Biotechnology Companies in Italy, 2019 – Chart 1	<u>124</u>
Figure 374.4.74. Distribution of Core Biotechnology Companies in Italy, 2019 – Chart 1	<u>125</u>
Figure 374.4.75. Core Biotechnology Companies in Major Italian Regions, 2019	<u>125</u>
Figure 374.4.76 Biotechnology Clusters in Italy: Lombardy, Segments 2019	<u>126</u>
Figure 374.4.77 Biotechnology Companies in Italy: Lombardy, 2019	<u>126</u>
Figure 374.4.78 Biotechnology Clusters in Italy: Cagliari-Pula, 2019	<u>127</u>
Figure 374.4.79 Biotechnology Clusters in Italy: Sicily, Etna Valley, 2019	<u>128</u>
Figure 374.4.80 Biotechnology Clusters in Italy: Other Areas, 2019	<u>128</u>
Figure 374.4.81. Biotechnology Companies in Italy: Other Areas, 2019	<u>129</u>
Figure 374.4.82 Biotechnology Companies in Italy: Cagliari-Pula, 2019	<u>129</u>
Figure 374.4.83 Biotechnology Companies in Italy: Sicily-Etna Valley, 2019	<u>130</u>
Figure 374.4.84. Switzerland Life Sciences Companies, 2018/19	<u>131</u>
Figure 374.4.85 Switzerland Market Promotional Features, 2019	<u>132</u>
Figure 374.4.86 Life Science Funding Status in Switzerland, 2019	<u>134</u>
Figure 374.4.87 Distribution of Biotechnology Industry Applications in Switzerland, 2019	<u>136</u>
Figure 374.4.88 Biotechnology Clusters in Switzerland, 2019	<u>137</u>
Figure 374.4.89 BioValley and BioAlps Clusters in Switzerland	<u>138</u>
Figure 374.4.90 Other Biotechnology Clusters in Switzerland	<u>139</u>
Figure 374.4.91 Sample Biotechnology Companies in Switzerland, 2019	<u>140</u>
Figure 374.4.92 Competitive Government Funding Schemes in UK, Historical	<u>144</u>
Figure 374.4.93. Competitive UK Government Funding via TSB/Innovate UK, 2012 – 2019	<u>146</u>
Figure 374.4.94. Biomedical Catalyst Programme in United Kingdom Awards, 2018/19	<u>147</u>
Figure 374.4.95 United Kingdom Market Promotional Features, 2019	<u>148</u>
Figure 374.4.96 United Kingdom Life Sciences Structure and Revenues, 2018	<u>151</u>
Figure 374.4.97 Biotechnology Funding Status in United Kingdom, 2019	<u>152</u>
Figure 374.4.98 UK Business Environment & Structural Events with Strategic Impact	<u>154 - 157</u>

Figure 374.4.99 Wellcome Foundation Science Support, 2019	159
Figure 374.4.100 Cancer Research UK Research Network, 2019	160
Figure 374.4.101 CRCUK Cancer Research Support, 2019	161
Figure 374.4.102 Total UK Bioeconomy Company Distribution, 2019	164
Figure 374.4.103 Core UK Biotechnology Application Areas, 2019 (& 2017)	164
Figure 374.4.104 Biomedical Research Units (BRUs) in UK, 2019	166
Figure 374.4.105 Biotechnology Clusters in the United Kingdom – Cambridge	167
Figure 374.4.106 Biotechnology Clusters in the United Kingdom – London	168
Figure 374.4.107 Biotechnology Cluster in the United Kingdom - Oxford	169
Figure 374.4.108 Biotechnology Clusters in the United Kingdom – Scotland	170
Figure 374.4.109 Biotechnology Clusters in the United Kingdom – Other Clusters	171
Figure 374.4.110 UK Biotechnology Cluster Focus Areas & Key Features, 2019	173
Figure 374.4.111 UK Science Park Examples with Biotechnology Focus, 2019	174
Figure 374.4.112 Biotechnology Funding Status in Austria, 2019	176
Figure 374.4.113 Distribution of Biotechnology Industry in Austria, 2019	178
Figure 374.4.114 Biotechnology Clusters in Austria: Vienna Region, 2019	179
Figure 374.4.115 Biotechnology Clusters in Austria – Outside of Vienna, 2019	180
Figure 374.4.116 Austrian Biotechnology & Pharma Data by Federal State, 2019	181
Figure 374.4.117 Ireland Market Promotional Features, 2019	182
Figure 374.4.118 Ireland Biotechnology Strategy Structure, 2019	183
Figure 374.4.119 Ireland R&D Budget 2018 by Main Functions	186
Figure 374.4.120 Ireland R&D Performance by Government Sector – 2018	187
Figure 374.4.121 Ireland Overall R&D Contribution by Source – 2018	188
Figure 374.4.122 Life Science Research Resources by Biotech Sector, Ireland 2018	189
Figure 374.4.119 Life Science Research Programmes with Biotechnology, Ireland 2015	190
Figure 374.4.120 Biotechnology in Life Science Research Strategy for Ireland	191
Figure 374.4.121 Biotechnology Business Application Areas Ireland, 2019	192
Figure 374.4.125 Examples of Funded Biotechnology Projects, Ireland	192



Figure 374.4.126 Biotechnology Clusters in Ireland & Northern Ireland – Dublin & Belfast	194
Figure 374.4.127 Biotechnology Clusters in Ireland & Northern Ireland – Other Clusters	195

5. Group 2 Nordic Countries – Life Science & BioResearch Analysis 196

Figure 374.4.128 Denmark Nanotechnology & Biotechnology Applications, 2019	198
Figure 374.4.129 Denmark Centres for Biotechnology Research, 2019	204
Figure 374.4.130 Denmark Companies & Funding Activities, 2019	205
Figure 374.4.131. Research Funding Budget Allocations in Finland, 2019 vs. 2016	209
Figure 374.4.132 Biotechnology Funding Status in Finland, 2019	210
Figure 374.4.133 Finland Core Biotechnology Company Sector Areas, 2019	212
Figure 374.4.134 Finland Biotechnology Applications Areas, 2019	212
Figure 374.4.135 Finland Government Support for Biotechnology, 2019	213
Figure 374.4.136 Biotechnology Clusters in Finland	216
Figure 374.4.137 Finland Biotechnology Research Companies, 2019	217
Figure 374.4.138 Funding Status in Norway, 2019	223
Figure 374.4.139 Norway Core Biotechnology Research Companies, 2019	224
Figure 374.4.140 Norway Biotechnology Commercial Companies, 2019	225
Figure 374.4.141 Universities in Norway with Biotechnology Activities, 2019	227
Figure 374.4.142 Life Science Funding Status in Sweden, 2019	230
Figure 374.4.143. Sweden Biotechnology Companies, 2019	232
Figure 374.4.144 Sweden Biotechnology Application Areas, 2019	233
Figure 374.4.145. Biotechnology Academic Research Facilities, 2019	234
Figure 374.4.146 Sweden Biotechnology Cluster & Company Distribution, 2019	237
Figure 374.4.147 General Biotechnology Clusters in Sweden, 2019	237
Figure 374.4.148 Danish & Swedish Patent Applications for Technology, 2008-2017	240



Figure 374.4.149 General Biotechnology Research Citations for Sweden, 2008-2017	241
Figure 374.4.150 Status for Scanbalt Region of Northern Europe, 2019	243
Figure 374.4.151 Swedish Biotechnology Research Companies, 2019	244
Figure 374.4.152 Iceland Biotechnology Research Companies, 2016	251
Figure 374.4.153 Nordic Region Life Science Businesses, 2019	252
6. Group 3 Benelux Countries – Life Science & BioResearch Analysis	253
Figure 374.4 154 Funding Status in Belgium, 2019	255
Figure 374.4 155 Flanders.bio Range of Participants, 2019	257
Figure 374.4.156 Sample Biotechnology Companies in Flanders, 2019	257
Figure 374.4.157 Structure of Bio-Win in Wallonia, Belgium 2019	260
Figure 374.4.158 Applications of Bio-Win Members in Wallonia, Belgium, 2019	261
Figure 374.4.159 Biotechnology Research Companies in Wallonia, 2019	262
Figure 374.4.160 Brussels-Capital Region Biotechnology Research Companies, 2019	264
Figure 374.4.161 Biotechnology Regional Focus Areas in Belgium, 2019	265
Figure 374.4.162 Data Base of Dutch Biotechnology Companies by Application, 2019	271
Figure 374.4.163 Biotechnology Activity Status in The Netherlands, 2018	272
Figure 374.4.164 Funding Status in The Netherlands, 2019	274
Figure 374.4.165 Biotechnology Clusters in The Netherlands – Amsterdam	276
Figure 374.4.166 Biotechnology Clusters in The Netherlands – Leiden	277
Figure 374.4.167 Biotechnology Clusters in The Netherlands – Northern Netherlands	278
Figure 374.4.168 Biotechnology Clusters in The Netherlands – Utrecht	279
Figure 374.4.169 Biotechnology Clusters in The Netherlands – Other Clusters	280
Figure 374.4.170 Companies in the Health Tech Cluster in Luxembourg, 2019	286
Figure 374.4.171 Benelux Country Overview Figures, 2019	287



7. Group 4 Iberian Countries - Life Science & BioResearch Analysis _____ 288

Figure 374.4.172 Life Science Companies in Spain, 2018 _____ 292

Figure 374.4.173 Biotechnology Application Areas in Spain, 2019 _____ 293

Figure 374.4.174 Spanish Biotechnology Research Companies, 2019 _____ 295

Figure 374.4.175 Regional Distribution of Biotechnology in Spain, 2019 _____ 300

Figure 374.4.176 Higher Education Facilities Distribution in Portugal, 2019 _____ 303

Figure 374.4.177 Portuguese Biotechnology Research Laboratories, 2019 _____ 306

Figure 374.4.178 Biotechnology Sector Funding Status in Portugal, 2019 _____ 307

Figure 374.4.179 Biotechnology Research Funding Sources in Portugal, 2019 _____ 308

Figure 374.4.180 Biotechnology Research Funding Segment
Applications in Portugal, 2019 _____ 308

Figure 374.4.181 Portuguese Biotechnology Research Companies, 2019 _____ 309

Figure 374.4.182 Biotechnology Budget Funding Sources
Iberian Countries, € million 2019 _____ 310

8. Biotechnology Applications & Products _____ 311

Figure 374.4.183 Life Science Research Product Listings, 2019 _____ 312

Figure 374.4.184 Life Science Research Focus & Product Demands in Europe _____ 313

Figure 374.4.185 Leading Healthcare Trends Affecting Life Science Research, 2019 _____ 316

Figure 374.4.186 Red Biotechnology Products & Services _____ 317

Figure 374.4.187 European Perspective of BioFuel Markets & Dynamics, 2019 _____ 327

Figure 374.4.188 BioPlastic Industry Business Profile _____ 329

Figure 374.4.189 Molecular Diagnostic Technologies Global Estimate, 2019 _____ 334

Figure 374.4.190 Epigenetics Research Tools & Applications, 2019 _____ 337

Figure 374.4.191 Systems Biology & Interactions _____ 339

Figure 374.4.192 Applications Share for
BioResearch Products, Europe, 2016, 2019 & 2024 _____ 352



9. Biotechnology Market Segments & Funding _____ 353

Figure 374.4.193 European Biotechnology Company Distribution by Country, 2019 _____	354
Figure 374.4.194 Core Biotechnology Research Market Segment Facilities, 2019 _____	355
Figure 374.4.195 Biotech Market Segments by Approximate Research Groups	
Europe 2019 _____	356
Figure 374.4.196 Life Science Funding by Source in Europe	
by Country, 2019 in million euros _____	357
Figure 374.4.197 European BioResearch Funding Sources, 2016 _____	359
Figure 374.4.198 European BioResearch Funding Sources, 2019 _____	359
Figure 374.4.199 Biotech Market by Segment Allocation, 2016 _____	360
Figure 374.4.200 European BioResearch Funding Sources, Projection 2024 _____	361
Figure 374.4.201 Life Science Funding & Product Markets – by Segment, Europe 2019 _____	363
Figure 374.4.202 Life Science Research Products Segment Distribution, 2019 (& 2016) _____	364

10. Biotechnology Market Quantification & Projection _____ 368

Figure 374.4.203 Biotechnology as a Sector & Enabling Technology, 2019 _____	368
Figure 374.4.204 Life Science Research Product Markets – Europe 2019 & 2024 _____	370
Figure 374.4.205 Life Science Research Equipment Product Markets – Europe 2019 _____	371
Figure 374.4.206 European Total Research Reagent Product Market Shares, 2019 _____	372
Figure 374.4.207 European Country Product Group Sales, 2019 _____	374
Figure 374.4.208 European BioResearch Reagent Product Group Sales, 2019 _____	376
Figure 374.4.209 European BioResearch Reagent Product Class Sales, 2019 _____	377
Figure 374.4.210 Germany BioResearch Reagent Product Group Sales, 2019 _____	379
Figure 374.4.211 UK BioResearch Reagent Product Group Sales, 2019 _____	380
Figure 374.4.212 Biotechnology Sector Development Stage S-Curve, 2019 _____	382
Figure 374.4.213 S-Curve Technology Development – General Dynamics _____	388
Figure 374.4.214 Technology Development Model for Reagents & Arrays Europe, 2019 _____	389
Figure 374.4.215 Technology Development Model for Equipment Groups, Europe, 2019 _____	391
Figure 374.4.216 Strategic Comparison of Major BioResearch Players, 12-month figures to December 2019 _____	393
Figure 374.4.217 Strategic Comparison of Major BioResearch Players, 12-month figures to December 2016 _____	394
Free page for own notes _____	399.